Discover

AVGR
Avinger, Inc.
0.47
undefined x undefined
undefined x undefined
bid
ask
-
0.12
20.74%
04:00 PM
Ytd -42.05%
1y -83.66%
0.46
day range
0.61
undefined
52 week range
undefined
Open 0.56 Prev Close 0.60 Low 0.46 High 0.61 Mkt Cap N/A
Vol 2.59M Avg Vol 0.00 EPS N/A P/E N/A Forward P/E -1.23
Beta 1.16 Short Ratio 0.22 Inst. Own 2.84% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning N/A 50-d Avg N/A 200-d Avg N/A 1yr Est 5.00
Earning
Date For Estimate Reported Surprise surprise %
2024-11-07 2024-09 -2.03 -1.82 0.21 10.34%
2024-08-08 2024-06 -0.43 -2.82 -2.39 -555.81%
2024-05-15 2024-03 -1.35 -2.49 -1.14 -84.44%
2024-03-20 2023-12 0.64 -3.93 -4.57 -714.06%
2023-10-26 2023-09 -2.85 -2.92 -0.07 -2.46%
2023-07-27 2023-06 -7.35 -8.85 -1.5 -20.41%
Upgrade / Downgrade
Date Firm Action From To
2024-03-21 HC Wainwright & Co. Upgrade Buy Buy
2024-03-08 HC Wainwright & Co. Upgrade Buy Buy
2023-11-13 HC Wainwright & Co. Upgrade Buy Buy
Profile
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Insider Holder
Date Name Relation Quantity Description
2024-01-10 CULLEN JAMES G Director 29.90K Stock Award(Grant)
2024-01-10 ELIAS TAMARA N. M.D. Director 29.96K Stock Award(Grant)
2024-01-10 MCELWEE JAMES B Director 29.90K Stock Award(Grant)
2024-01-17 PATEL HIMANSHU T Chief Technology Officer 41.28K Stock Award(Grant)
2024-01-17 SOINSKI JEFFREY MARTIN Chief Executive Officer 58.96K Stock Award(Grant)
2023-03-22 SUBAINATI NABEEL PAUL Officer 85.67K Sale
Institution Ownership
Report Date Organization Position Value Percentage
2024-09-29 Armistice Capital, LLC 81.00K 117.45K 2.45%
2024-09-29 UBS Group AG 26.17K 37.95K 0.79%
2024-09-29 Vanguard Group Inc 23.80K 34.51K 0.72%
2024-09-29 Blackrock Inc. 4.90K 7.10K 0.15%
2024-09-29 Tower Research Capital LLC (TRC) 4.13K 5.98K 0.12%
2024-09-29 City State Bank 225.00 326.00 0.01%
Fund Ownership
Report Date Organization Position Value Percentage
2024-09-29 Vanguard Extended Market Index Fund 23.80K 34.51K 0.72%
2024-10-30 Fidelity Extended Market Index Fund 6.94K 10.06K 0.21%
2024-10-30 Fidelity Series Total Market Index Fund 2.86K 4.14K 0.09%
2024-10-30 Fidelity Total Market Index Fund 513.00 743.00 0.02%
2024-09-29 Blackstone Alternative Multi-Strategy Fund 34.00 49.00 0.00%
Split
Split Date
1 : 15 2023-09-13
1 : 20 2022-03-15
1 : 10 2019-06-24
1 : 40 2018-01-31